key: cord-0993351-zlx4zb97 authors: Filkins, Laura; SoRelle, Jeffrey A; Schoggins, John; Park, Jason Y title: Laboratory action plan for emerging SARS-CoV-2 variants date: 2021-01-30 journal: Clin Chem DOI: 10.1093/clinchem/hvab020 sha: 12081273cdd5cf5a76cf6c4b48779270b5eeadc7 doc_id: 993351 cord_uid: zlx4zb97 nan In December 2020, a clinically significant SARS-CoV-2 variant with an increased transmission rate was identified in the United Kingdom (1) (2) (3) . Currently referred to as SARS-CoV-2 VOC-202012/01 (Variant of Concern, year 2020, month 12, variant; VOC-202012/01) or the B.1.1.7 variant, it has been identified in multiple countries throughout the world and continues to spread unabatedly (1, 4) . VOC-202012/01 appears to be detectable by commonly used nucleic acid-based tests with emergency use authorization (EUA) from the United States Food and Drug Administration (FDA), and hopefully will not present a diagnostic challenge for clinical laboratories. As the COVID-19 pandemic continues, we anticipate additional clinically significant SARS-CoV-2 variants will emerge and we propose several preparatory actions for clinical laboratories. VOC-202012/01 was identified in a genomic sequencing investigation of a rapid increase in COVID-19 cases in South East England. VOC-202012/01 was detected in approximately 50% of the increased cases. A retrospective investigation identified the earliest case from September 20, and by December 13 there were 1,108 cases identified (1, 2, 5) . Despite increased potential transmissibility, there is currently no evidence indicating increased severity of disease or decreased efficacy of vaccines of this variant (4) . Reassuringly, antibody responses to vaccine epitopes indicate the genetic changes of the new variant are outside of major antibody binding sites (6). An evaluation of the Pfizer/BioNTech vaccine suggests efficacy against VOC-202012/01 (7) . VOC-202012/01 has 17 genetic changes affecting amino acid sequence (missense, deletions, early stop codon) (2) ( Table 1) ; eight of these genetic changes occur in the S (spike) gene domain. The overall number of genetic changes is considered large compared to other SARS-CoV-2 variants. Globally, most SARS-CoV-2 variants have only a few genetic changes and are estimated to accumulate at a rate of 1-2 per month (2, 8) . Current speculation is that the high number of genetic changes in VOC-202012/01 may be due to a rapid selection pressure event such as a prolonged infection in a patient with reduced immunocompetence (1, 9, 10) or that the variant developed within an infected animal and was transmitted back to humans (1, 11) . However, in general, coronavirus genomes are relatively genetically stable, particularly when compared to RNA viruses like influenza A virus. This is because coronaviruses encode a proofreading mechanism to reduce mutations, whereas influenza A virus and many other RNA viruses have low fidelity, error-prone polymerases (12, 13) . Thus, additional knowledge about host pressures that led to the emergence of VOC-202012/01 will be informative from the standpoint of viral evolution. VOC-202012/01 genetic changes are present in multiple genes, including those commonly targeted by SARS-CoV-2 diagnostic tests: ORF1ab, S-gene, N-gene. As of January 8, 2021, there are two nucleic acid-based tests known to be impacted by VOC-202012/01 (TaqPath COVID-19 Combo Kit (TaqPath), Linea COVID-19 Assay Kit (Linea)); a third test, (MesaBiotech Accula (Accula)), may be affected by SARS-CoV-2 variants with a genetic change not present in VOC-202012/01 (14) . The TaqPath and Linea assays are impacted by S gene genetic changes in VOC-202012/01; however, the overall sensitivity of these two assays is not known to be affected (14) . The TaqPath assay is a multiplex real-time reverse transcription PCR test that targets the ORF1ab, S and N genes; only the S-gene target is affected due to deletion of genome nucleotides 21765_21770del (His69_Val70del). The Linea assay includes two targets within the S-gene; only one target is affected. A patient sample with VOC-202012/01 will have a negative amplification signal in the S gene target, but positive amplification signals in the ORF1ab and N gene targets using the TaqPath assay (2 of 3 targets positive) and the Linea assay will yield 1 of 2 positive S-gene targets. Of note, the implicated deletion (His69_Val70del) is not exclusive to VOC-202012/01. Manufacturers of other major assays have thus far reassured laboratories that there is no predicted impact on individual target detection or qualitative detection of SARS-CoV-2 due to the genetic changes in VOC-202012/01 or other SARS-CoV-2 variants. Since the emergence of SARS-CoV-2, clinical laboratories, regulators and manufacturers have anticipated that genetic changes could occur and potentially impact testing. At the outset of the pandemic, since there was limited knowledge of the conserved genetic regions of SARS-CoV-2, diagnostic assays were made with multiple targets to enable positive detection even if a single target became impacted by genetic changes. However, single-target SARS-CoV-2 nucleic acid tests were also developed due to early challenges in validating and maintaining adequate supplies; these single-target assays remain in use. As of January 13, 2021, 83% (152 of 192) of nucleic acid amplification assays with FDA EUA have more than one target for detection (15) . Clinical laboratories should develop a strategy for how they will address VOC-202012/01 and prepare for new SARS-CoV-2 variants. As the pandemic continues, there is a possibility of future genetic changes that significantly impact test performance. To date, changes in detection of VOC-202012/01 are not reported for any assays with US FDA EUA and the only individual target with reported altered detection is the S gene within the TaqPath and Linea assays; other S gene-targeting assays are not apparently affected (14) . Assurances of assay performance by manufacturers have been mostly based on in silico analyses. When the designs of primers/probes are publicly available, laboratories should perform in silico analysis to assess the potential impact. In addition, in silico predictions should be confirmed on biologic materials (e.g., patient samples or inactivated virus). Genetic changes may not cause a total loss in signal, but may lead to decreased (or increased) detection efficiency. Therefore, laboratories should consider confirming assay limit of detection when: 1) the new variant becomes prevalent within the population tested and 2) quantified reference materials become available to determine analytic sensitivity. Laboratories should work with manufacturers, regulators and public health authorities to quickly coordinate an approach to identifying and distributing emerging SARS-CoV-2 variants to challenge existing assay systems. At a minimum, assays with EUA should be assessed for the potential impact of SARS-CoV-2 variants by direct laboratory examination in addition to in silico predictions. While the current focus is on nucleic acid tests, the impact on antigen tests warrants further investigation. After recognition of an emerging variant, screening protocols need to be developed. For example, the TaqPath assay has been implemented as part of a two-step screening process for VOC-202012/01 where positive samples with a negative S gene target are further evaluated by whole genome sequencing (16) . This strategy effectively identifies the His69_Val70del but is not specific for VOC-202012/01. Public Health England used this two-step strategy in their investigation of VOC-202012/01 (5) . In the US, a two-step process screening with S-gene negative tests (e.g., TaqPath) reflexing to whole genome sequencing is feasible, but coordination and centralization of data need to be implemented. There are multiple labs in the US that provide SARS-CoV-2 whole genome sequencing for diagnosis; these laboratories need to be coordinated with existing genomic sequencing surveillance networks. The integration of testing laboratories, public health authorities and genomic surveillance networks needs to occur for the rapid identification of not only VOC-202012/01 but additional emerging SARS-CoV-2 variants. While most clinical laboratories are not equipped to perform extensive surveillance, many assays provide information that can be leveraged as first-line surveillance tools. For example, laboratories performing multi-target assays that report individual target cycle threshold (Ct) values should consider monitoring the expected relative differences in Ct values of multiple targets. Patient samples with discordant results across multiple target genes should be investigated (e.g., negative S-gene in an overall positive TaqPath assay). If multiple samples have the same pattern of target gene discordance, especially when high viral loads are detected, these data should be shared with public health authorities and further investigated. Whenever feasible, laboratories should correlate epidemiologic data with the emergence of samples with target gene discordance. The collection date and origin should be monitored, and public health laboratories should consider associating the emergence of variants with illness severity or clusters within household or contacts. Additionally, laboratories routinely employing genome sequencing-based assays, such as the Illumina COVIDSeq Test or BillionToOne qSanger-COVID-19 Assay, may consider performing variant monitoring as part of their routine quality assessment program. Chronic infection can occur in immunocompromised hosts resulting in long-term infectious viral shedding and constant turnover of viral variants up to 100 days after infection (17) . To better understand the evolution of SARS-CoV-2 and monitor for emerging or highly divergent variants, there should be consideration for specialized testing of patients with prolonged COVID-19 positivity (e.g., multiple strong positive nucleic acid test results over at least a month). Furthermore, patients with prior documented COVID-19 that have a new positive SARS-CoV-2 test results after a period of negativity (re-infection), or >90 days after their first documented positive should be considered for more intensive evaluation of novel variants (e.g., whole genome sequencing). VOC-202012/01 is a strong reminder that virus evolution and genetic variation can impact both their fitness and their detection by diagnostic assays. Although laboratories throughout the world have already weathered a year of relentless challenges in the COVID-19 pandemic, there is much more work to be continued. Addressing VOC-202012/01 and other emerging SARS-CoV-2 variants is the first task of the new year. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. Threat Assessment Brief. European Centre for Disease Prevention and Control Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 Emerging SARS-CoV-2 Variants Investigation of novel SARS-COV-2 variant, Variant of Concern 202012/01; Technical Briefing 1 Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera Temporal signal and the evolutionary rate of 2019 n-CoV using 47 genomes collected by Persistence and evolution of SARS-CoV-2 in an immunocompromised host Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape Working paper on SARS-CoV-2 spike mutations arising in Danish mink, their spread to humans and neutralization data. SARS-CoV-2 spike mutations arising in Danish mink and their spread to humans Coronavirus RNA proofreading: Molecular basis and therapeutic targeting Low genetic diversity may be an Achilles heel of SARS-CoV-2 Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2. Letter to Clinical Laboratory Staff and Health Care Providers Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer